Jupiter Asset Management Ltd. Purchases Shares of 194,036 Royalty Pharma plc (NASDAQ:RPRX)

Jupiter Asset Management Ltd. purchased a new stake in Royalty Pharma plc (NASDAQ:RPRX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 194,036 shares of the biopharmaceutical company’s stock, valued at approximately $4,950,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RPRX. Swedbank AB grew its stake in shares of Royalty Pharma by 2.0% during the third quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock valued at $311,964,000 after purchasing an additional 213,900 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Royalty Pharma by 1.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,009,541 shares of the biopharmaceutical company’s stock valued at $28,560,000 after purchasing an additional 15,963 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Royalty Pharma by 26.8% during the third quarter. Victory Capital Management Inc. now owns 849,035 shares of the biopharmaceutical company’s stock valued at $24,019,000 after purchasing an additional 179,411 shares during the last quarter. KBC Group NV grew its stake in shares of Royalty Pharma by 63.1% during the third quarter. KBC Group NV now owns 41,554 shares of the biopharmaceutical company’s stock valued at $1,176,000 after purchasing an additional 16,081 shares during the last quarter. Finally, Metis Global Partners LLC grew its stake in shares of Royalty Pharma by 10.8% during the third quarter. Metis Global Partners LLC now owns 21,737 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 2,126 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Trading Down 0.5 %

Shares of NASDAQ RPRX opened at $32.68 on Friday. The company’s 50 day simple moving average is $31.45 and its 200 day simple moving average is $28.53. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The firm has a market capitalization of $18.84 billion, a P/E ratio of 22.54, a P/E/G ratio of 2.31 and a beta of 0.47. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a $0.22 dividend. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.69%. The ex-dividend date of this dividend was Friday, February 21st. Royalty Pharma’s dividend payout ratio is currently 60.69%.

Wall Street Analyst Weigh In

Separately, TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.